TrialHaematologica2023

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Michelle Hudspeth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.